Growth factor delivery for bone tissue repair: an update

Bibliography

• GITTENS SA, ULUDAG H: Growth factor delivery for bone tissue engineering. .1. Drug Target. (2001) 9:407–429.
   PubMed Web of Science ®Google Scholar
• ROSE FR, HOU Q, OREFFO RO: Delivery systems for bone growth factors - the new players in skeletal regeneration. .1. Pharm. Pharmacol. (2004) 56:415–427.
   PubMed Web of Science ®Google Scholar
• GAMRADT SC, LIEBERMAN JR: Genetic modification of stem cells to enhance bone repair. Ann. Biomed. Eng. (2004) 32:136–147.
   PubMed Web of Science ®Google Scholar
• BALTZER AW, LIEBERMAN JR: Regional gene therapy to enhance bone repair. Gene The]: (2004) 11:344–350.
   PubMed Web of Science ®Google Scholar
• PULEO D: Biotherapeutics in orthopaedic medicine: accelerating the healing process? BioDrugs (2003) 17:301–314.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA M, REDDI AH: The application of bone morphogenetic proteins to dental tissue engineering. Nat. Biotech. (2003) 21:1025–1032.
   PubMed Web of Science ®Google Scholar
• KING GN, COCHRAN DL: Factors that modulate the effects of bone morphogenetic protein-induced periodontal regeneration: a critical review. J. Periodontol. (2002) 73:925–936.
   PubMed Web of Science ®Google Scholar
• LI RH, WOZNEY JM: Delivering on the promise of bone morphogenetic proteins. Trends Biotech. (2001) 19:255–265.
   PubMed Web of Science ®Google Scholar
• CHENG JCY, GUO X, LAW LP, LEE KM, CHOW DHK, ROSIER R: How does recombinant human bone morphogenetic protein-4 enhance posterior spinal fusion? Spine (2002) 27:467–474.
   PubMed Web of Science ®Google Scholar
• VALENTIN-OPRAN A, WOZNEY J, CSIMMA C, LILLY L, RIEDEL GE: Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin. Orthop. (2002) 395:110–120.
   PubMed Web of Science ®Google Scholar
• GOVENDER S, CSIMMA C, GENANT HK, VALENTIN-OPRAN A, THE BESTT STUDY GROUP,, et al.: Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures - a prospective, controlled, randomized study of four hundred and fifty patients. J. Bone John Sorg. Am. (2002) 84-A:2123–2134.
   Google Scholar
• BURKUS JK, HEIM TE, GORNET ME ZDEBLICK TA: Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. Spinal Disord. Tech. (2003) 16:113–122.
   PubMed Web of Science ®Google Scholar
• BURKUS JK, GORNET ME DICKMAN CA, ZDEBLICK TA: Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J. Spinal Disord. Tech. (2002) 15:337–349.
   PubMed Web of Science ®Google Scholar
• BURKUS JK, DORCHAK JD, SANDERS DL: Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein Type 2. Spine (2003) 28:372–377.
   PubMed Web of Science ®Google Scholar
• BODEN SD, GROB D, DAMIEN C: Ne-Osteo bone growth factor for posterolateral lumbar spine fusion: results from a non-human primate study and a prospective human clinical pilot study. Spine (2004) 29:504–514.
   PubMed Web of Science ®Google Scholar
• VACCARO AR, PATEL T, FISCHGRUND J et al: A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Ear: Spine .1. (2003) 12:495–500.
   Google Scholar
• SETO I, ASAHINA I, ODA M, ENOMOTO S: Reconstruction of the primate mandible with a combination graft of recombinant human bone morphogenetic protein-2 and bone marrow. J. Oral Maxillofac. Surg. (2001) 59:53–61.
   PubMed Web of Science ®Google Scholar
• BOYNE PJ: Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J. Bone John Sorg. Am. (2001) 83-A: S146–S150.
   Google Scholar
• MARUKAWA E, ASAHINA I, ODA M, SETO I, LAM M, ENOMOTO S: Functional reconstruction of the non-human primate mandible using recombinant human bone morphogenetic protein-2. Int. I Oral Maxillofac Surg. (2002) 31:287–295.
   PubMed Web of Science ®Google Scholar
• MARUKAWA E, ASAHINA I, ODA M, SETO I, ALAM MI, ENOMOTO S: Bone regeneration using recombinant human bone morphogenetic protein-2 (rhBMP-2) in alveolar defects of primate mandibles. Br. J. Oral Maxillofac. Surg. (2001) 39:452–459.
   PubMed Web of Science ®Google Scholar
• SEEHERMAN H, WOZNEY JM, LI R: Bone morphogenetic protein delivery systems. Spine (2002) 27:16S–23S.
   PubMed Web of Science ®Google Scholar
• SUH DY, BODEN SD, LOUIS-UGBO J et al: Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine (2002) 27:353–360.
   PubMed Web of Science ®Google Scholar
• AKAMARU T, SUH D, BODEN SD, KIM HA, MINAMIDE A, LOUIS-UGBO J: Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine (2003) 28:429–434.
   PubMed Web of Science ®Google Scholar
• HANISCH O, SORENSEN RG, KINOSHITA, SPIEKERMANN H, WOZNEY JM, WIKESJO UM: Effect of recombinant human bone morphogenetic protein-2 in dehiscence defects: an experimental study in cynomolgus monkeys. J. Periodontol. (2003) 74:648–657.
   PubMed Web of Science ®Google Scholar
• SHEEHAN JP, SHEEHAN JM, SEEHERMAN H, QUIGG M, HELM GA: The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model. J. Neurawrg. (2003) 98:125–130.
   PubMed Web of Science ®Google Scholar
• RIPAMONTI U, CROOKS J, RUEGER DC: Induction of bone formation by recombinant human osteogenic protein-1 and sintered porous hydroxyapatite in adult primates. Plast. Reconsm. Sorg. (2001) 107:977–988.
   PubMed Web of Science ®Google Scholar
• RIPAMONTI U, CROOKS J, PETIT JC, RUEGER DC: Periodontal tissue regeneration by combined applications of recombinant human osteogenic protein-1 and bone morphogenetic protein-2: a pilot study in Chacma baboons (Papio ursinus). Eur: J. Oral Sci. (2001) 109 (4) :241–248.
   PubMed Web of Science ®Google Scholar
• COOK SD, SALKELD SL, SARGENT MC, RUEGER DC: Healing course of primate ulna segmental defects treated with osteogenic protein-1." Invest. Surg. (2002) 15:69–79.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA S, MURAKAMI S, SHIMABUKURO Y, KITAMURA M, OKADA H: Periodental regeneration by FGF-2 (bFGF) in primate models. I Dent. Res. (2001) 80:2075–2079.
   PubMed Web of Science ®Google Scholar
• KAWAGUCHI H, NAKAMURA K, TABATA Y et al.: Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2. I Clin. Endocrinol Metab. (2001) 86:875–880.
   Google Scholar
• STEFFEN T, STOLL T, ARVINTE T, SCHENK RK: Porous tricalcium phosphate and transforming growth factor used for anterior spine surgery. Eat SpMei (2001) 10\(Suppl. 2): S132–S140.
   Google Scholar
• ULUDAG H, D' Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. Biomed. Mat. Res. (1999) 46:193–202.
   PubMed Web of Science ®Google Scholar
• BODEN SD, KANG J, SANDHU H, HELLER JG: Use of recombinant bone morphogenetic protein-2 to achieve posterolateral lumber spine fusion in human. Spine (2002) 27:2662–2673.
   PubMed Web of Science ®Google Scholar
• KUBOTA K, ISEKI S, KURODA S et al: Synergistic effect of fibroblast growth factor-4 in ectopic bone formation induced by bone morphogenetic protein-2. Bone (2002) 31:465–471.
   PubMed Web of Science ®Google Scholar
• SCHMIDMAIER G, WILDEMANN B, STEMBERGER A, HAAS NP, RASCHKE M: Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-betal) from a biodegradable poly (D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. Bone (2001) 28:341–350.
   PubMed Web of Science ®Google Scholar
• KANDZIORA F, SCHMIDMAIER G, SCHOLLMEIER G et al.: IGF-I and TGF-betal application by a poly-(D,L-lactide)-coated cage promotes intervertebral bone matrix formation in the sheep cervical spine. Spine (2002) 27:1710–1723.
   PubMed Web of Science ®Google Scholar
• KANDZIORA F, PFLUGMACHER R, SCHOLZ M et al.: Dose-dependent effects of combined IGF-I and TGF-I31 application in a sheep cervical spine fusion model. Eat Spine.! (2003) 12:464–473.
   PubMed Web of Science ®Google Scholar
• ULUDAG H, NORRIE B, KOUSINIORIS N, GAO T: Engineering temperature sensitive poly(N isopropylacrylamide) polymers as carriers of therapeutic proteins. Biotech. Bioeng. (2001) 73:510–521.
   PubMed Web of Science ®Google Scholar
• DEVOGELAER JP: A review of the effectsof tibolone on the skeleton. Expert Opin. Pharmacother. (2004) 5:941–949.
   PubMed Web of Science ®Google Scholar
• PUN S, DEARDEN RL, RATKUS AM, LIANG H, WRONSKI TJ: Decreased bone anabolic effect of basic fibroblast growth factor at fatty marrow sites in ovariectomized rats. Bone (2001) 28:220–226.
   Google Scholar
• WRONSKI TJ, RATKUS AM, THOMSEN JS, VULCAN Q, MOSEKILDE L: Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats. J. Bone Miner. Res. (2001) 16:1399–1407.
   PubMed Web of Science ®Google Scholar
• IWANIEC UT, MOSEKILDE L, MITOVA-CANEVA NG, THOMSEN JS, WRONSKI TJ: Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology (2002) 143: 2515–2526.
   Google Scholar
• POWER RA, IWANIEC UT, WRONSKI TJ: Changes in gene expression associated with the bone anabolic effects of basic fibroblast growth factor in aged ovariectomized rats. Bone (2002) 31:143–148.
   PubMed Web of Science ®Google Scholar
• LANE NE, YAO W, KINNEY JH, MODIN G, BALOOCH M, WRONSKI TJ: Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J. Bone Miner. Res. (2003) 18:2105–2115.
   PubMed Web of Science ®Google Scholar
• LANE NE, KUMERJ, YAO W et al: Basicfibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos. mt. (2003) 4(5):374–382.
   Google Scholar
• IWANIEC UT, MAGEE KA, MITOVA-CANEVA NG, WRONSKI TJ: Bone anabolic effects of subcutaneous treatment with basic fibroblast growth factor alone and in combination with estrogen in osteopenic ovariectomized rats. Bone (2003) 33:380–386.
   PubMed Web of Science ®Google Scholar
• POWER RA, IWANIEC UT, MAGEE KA et al.: Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats. Osteoporos. Int. (2004) (In Press).
   Google Scholar
• TURGEMAN G, ZILBERMAN Y, ZHOU S et al.: Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice.Biochem. (2002)86:461–474.
   Web of Science ®Google Scholar
• ANDRESS DL: IGF-binding protein-5 stimulates osteoblast activity and bone accretion in ovariectomized mice. Am. J. Physiol Endocrinol Metab. (2001) 281: E283–E288.
   PubMed Web of Science ®Google Scholar
• KAWATA T, TOKIMASA C, FUJITA T et al.: Effect of insulin-like growth factor-I (IGF-I) on femoral bone modeling in growing mice. Exp. Anim. (2002) 51:521–524.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER AL, BUTTERFIELD GE, MOYNIHAN S et al.: One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. Clin. Endocrinol Metab. (2001) 86:1496–1503.
   Google Scholar
• STABNOV L, KASUKAWA Y, GUO R et al.: Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. Bone (2002) 30:909–916.
   PubMed Web of Science ®Google Scholar
• KASUKAWA Y, STABNOV L, MIYAKOSHI N, BAYLINK DJ, MOHAN S: Insulin-like growth factor I effect on the number of osteoblast progenitors is impaired in ovariectomized mice. J. Bone Muter. Res. (2002) 17:1579–1587.
   PubMed Web of Science ®Google Scholar
• POYNTON AR, LANE JM: Safety profilefor the clinical use of bone morphogenetic proteins in the spine. Spine (2002) 27:S40–S48.
   PubMed Web of Science ®Google Scholar
• VUKICEVIC S, BASIC V, ROGIC D et al.: Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischaemic acute renal failure in rat. I. Clin. Invest. (1998) 102:202–214.
   PubMed Web of Science ®Google Scholar
• ZEISBERG M, BOTTIGLIO C, KUMAR N et al.: Bone morphogenetic protein inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. .1 Physiol Ren. Physiol (2003) 285:F1060–F1067.
   Google Scholar
• BIKFALVI A, KLEIN S, PINTUCCI G, RIFKIN DB: Biological roles of fibroblast growth factor-2. Endocrine Rev (1997) 18:26–45.
   PubMed Web of Science ®Google Scholar
• LIANG H, PUN S, WRONSKI TJ: Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology (1999) 140:5780–5788.
   PubMed Web of Science ®Google Scholar
• KLAMUT HJ, CHEN ST, LAU KH, BAYLINK DJ: Progress toward skeletal gene therapy. Grit. Rev Eukaryot. Gene Expr. (2004) 14:89–136.
   PubMed Web of Science ®Google Scholar
• WU D, RAZZANO P, GRANDE DA: Gene therapy and tissue engineering in repair of the musculoskeletal system. .1. Cell. Biochem. (2003) 88:467–481.
   PubMed Web of Science ®Google Scholar
• SCULLY SP: Gene therapy: clinical considerations. Clin Orthop. (2000) 379(Suppl.):S55–S58.
   Google Scholar
• CHEN Y, CHEUNG KM, KUNG HF, LEONG JC, LU WW, LUK KD: ha vivo new bone formation by direct transfer of adenoviral-mediated bone morphogenetic protein-4 gene. Biochem. Biophys. Res. Commun. (2002) 298:121–127.
   PubMed Web of Science ®Google Scholar
• CHEN Y, LUK KD, CHEUNG KM et al:Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Ther. (2003) 10:1345–1353.
   PubMed Web of Science ®Google Scholar
• CHEN Y, LUK KD, CHEUNG KM et al: Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats. Biochem. Biophys. Res. Commun. (2004) 317:675–681.
   PubMed Web of Science ®Google Scholar
• LI JZ, LI H, SASAKI T et al.: Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Titer. (2003) 10:1735–1743.
   Web of Science ®Google Scholar
• KAIHARA S, BESSHO K, OKUBO Y, SONOBE J, KAWAI M, IIZUKA T: Simple and effective osteoinductive gene therapy by local injection of a bone morphogenetic protein-2-expressing recombinant adenoviral vector and FK506 mixture in rats. Gene Ther. (2004) 11:439–447.
   PubMed Web of Science ®Google Scholar
• SONOBE J, OKUBO Y, KAIHARA S, MIYATAKE S, BESSHO K: Osteoinduction by bone morphogenetic protein 2-expressing adenoviral vector: application of biomaterial to mask the host immune response. Hum. Gene Ther. (2004) 15:659–668.
   PubMed Web of Science ®Google Scholar
• OKUBO Y, BESSHO K, FUJIMURA K, IIZUKA T, MIYATAKE SI: Osteoinduction by bone morphogenetic protein-2 via adenoviral vector under transient immunosuppression. Biochem. Biophys. Res. Commun. (2000) 267:382–387.
   PubMed Web of Science ®Google Scholar
• OKUBO Y, BESSHO K, FUJIMURA K, KAIHARA S, IIZUKA T, MIYATAKE S: The time course study of osteoinduction by bone morphogenetic protein-2 via adenoviral vector. Life Sci. (2001) 70:325–336.
   PubMed Web of Science ®Google Scholar
• OKUBO Y, BESSHO K, FUJIMURA K, IIZUKA T, MIYATAKE SI: In vitro and in vivo studies of a bone morphogenetic protein-2 expressing adenoviral vector. Bone Joint Surg. Am. (2001) 83-A:S99–S104.
   Google Scholar
• ALDEN TD, PITTMAN DD, HANKINS GR et al: In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector. Hum. Gene Ther. (1999) 10:2245–2253.
   PubMed Web of Science ®Google Scholar
• GONDA K, NAKAOKA T, YOSHIMURA K, OTAWARA-HAMAMOTO Y, HARRII K: Heterotopic ossification of degenerating rat skeletal muscle induced by adenovirus-mediated transfer of bone morphogenetic protein-2 gene. Bone Miner. Res. (2000) 15:1056–1065.
   PubMed Web of Science ®Google Scholar
• KAWAI M, BESSHO K, KAIHARA S et al.: Ectopic bone formation by human bone morphogenetic protein-2 gene transfer to skeletal muscle using transcutaneous electroporation. Hum. Gene Ther. (2003) 14(16):1547–1556.
   PubMed Web of Science ®Google Scholar
• ASHINOFF RL, CETRULO CL Jr, GALIANO RD et al.: Bone morphogenic protein-2 gene therapy for mandibular distraction osteogenesis. Ann. Plast. Surg. (2004) 52:585–590.
   Google Scholar
• ALDEN TD, BERES EJ, LAURENT JS et al.: The use of bone morphogenetic protein gene therapy in craniofacial bone repair. I Craniofac. Surg. (2000) 11(1):24–30.
   PubMed Web of Science ®Google Scholar
• LINDSEY WH: Osseous tissue engineering with gene therapy for facial bone reconstruction. Laryngoscope (2001) 111:1128–1136.
   PubMed Web of Science ®Google Scholar
• ALDEN TD, PITTMAN DD, BERES EJ et al.: Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. Neurosurg. (1999) 90(Suppl.):109–114.
   Google Scholar
• JANE JA Jr, DUNFORD BA, KRON A et al.: Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther. (2002) 6:464–470.
   PubMed Web of Science ®Google Scholar
• LI JZ, LI H, DUNFORD B et al.: Rat strain differences in the ectopic osteogenic potential of recombinant human BMP adenoviruses. Mol Ther. (2003) 8:822–829.
   PubMed Web of Science ®Google Scholar
• LI JZ, HANKINS GR, KAO C, LI H, KAMMAUFF J, HELM GA: Osteogenesis in rats induced by a novel recombinant helper-dependent bone morphogenetic protein-9 (BMP-9) adenovirus. I Gene Med. (2003) 5:748–756.
   PubMed Web of Science ®Google Scholar
• LUK KD, CHEN Y, CHEUNG KM, KUNG HF, LU WW, LEONG JC: Adeno-associated virus-mediated bone morphogenetic protein-4 gene therapy for in vivo bone formation. Biochem. Biophys. Res. Commun. (2003) 308:636–645.
   PubMed Web of Science ®Google Scholar
• RUNDLE CH, MIYAKOSHI N, KASUKAWA Y et al.: In vivo bone formation in fracture repair induced by direct retroviral-based gene therapy with bone morphogenetic protein-4. Bone (2003) 32:591–601.
   PubMed Web of Science ®Google Scholar
• VARADY P, LI JZ, CUNNINGHAM M et al.: Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum. Gene Ther. (2001) 12:697–710.
   PubMed Web of Science ®Google Scholar
• HELM GA, ALDEN TD, BERES EJ et al:Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. Neurosurg. (2000) 92 (Suppl.) :191–196.
   Google Scholar
• MEHRARA BJ, SAADEH PB, STEINBRECH DS et al.: Adenovirus-mediated gene therapy of osteoblasts M vitro and M vivo. 1 Bone Miner. Res. (1999) 14:1290–1301.
   Google Scholar
• TARKKA T, SIPOLA A, JAMSA T et al.: Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. Gene Med. (2003) 5:560–566.
   Web of Science ®Google Scholar
• JIN Q, ANUSAKSATHIEN O, WEBB SA, PRINTZ MA, GIANNOBILE WV: Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. Mol. Ther. (2004) 9:519–526.
   PubMed Web of Science ®Google Scholar
• TSUDA H, WADA T, ITO Y et al.: Efficient BMP-2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol. The]: (2003) 7:354–365.
   PubMed Web of Science ®Google Scholar
• BLUM JS, BARRY MA, MIKOS AG, JANSEN JA: In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum. Gene Ther. (2003) 14:1689–1701.
   PubMed Web of Science ®Google Scholar
• PARK J, PIES J, GELSE K et al.: Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther. (2003) 10:1089–1098.
   PubMed Web of Science ®Google Scholar
• WANG JC, KANIM LE, Y00 S, CAMPBELL PA, BERK AJ, LIEBERMAN JR: Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. Bone Joint Surg. Am. (2003) 85-A:905–911.
   PubMed Web of Science ®Google Scholar
• TSUCHIDA H, HASHIMOTO J, CRAWFORD E, MANSKE P, LOU J: Engineered allogeneic mesenchymal stem cells repair femoral segmental defect in rats. Orthop. Res. (2003) 21:44–53.
   PubMed Web of Science ®Google Scholar
• DRAGOO JL, SAMIMI B, ZHU M et al:Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads. I Bone Joint Surg. Br. (2003) 85:740–747.
   PubMed Web of Science ®Google Scholar
• DRAGOO JL, CHOI JY, LIEBERMAN JR et al: Bone induction by BMP-2 transduced stem cells derived from human fat. Orthop. Res. (2003) 21:622–629.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN JR, DALUISKI A, STEVENSON S et al.: The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J. Bone Joint Surg. Am. (1999) 81:905–917.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN JR, LE LQ, WU L et al: Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. I Orthop. Res. (1998) 16:330–339.
   PubMed Web of Science ®Google Scholar
• PENG H, CHEN ST, WERGEDAL JE et al.: Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. Mol. Ther. (2001) 4:95–104.
   PubMed Web of Science ®Google Scholar
• PENG H, USAS A, GEARHART B, OLSHANSKI A, SHEN HC, HUARD J: Converse relationship between M vitro osteogenic differentiation and in vivo bone healing elicited by different populations of muscle-derived cells genetically engineered to express BMP4. J. Bone Miner. Res. (2004) 19:630–641.
   PubMed Web of Science ®Google Scholar
• ROSE T, PENG H, USAS A et al.: Genetherapy to improve osteogenesis in bone lesions with severe soft tissue damage. Langenbecks Arch. Surg. (2003) 388:356–365.
   PubMed Web of Science ®Google Scholar
• ROSE T, PENG H, SHEN HC et al.: The role of cell type in bone healing mediated by ex vivo gene therapy. Langenbecks Arch. Surg. (2003) 388:347–355.
   PubMed Web of Science ®Google Scholar
• GYSIN R, WERGEDAL JE, SHENG MH et al.: Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in rats. Gene Ther. (2002) 9:991–999.
   PubMed Web of Science ®Google Scholar
• HIDAKA C, GOSHI K, RAWLINS B, BOACHIE-ADJEI O, CRYSTAL RG: Enhancement of spine fusion using combined gene therapy and tissue engineering BMP-7-expressing bone marrow cells and allograft bone. Spine (2003) 28:2049–2057.
   PubMed Web of Science ®Google Scholar
• KREBSBACH PH, GU K, FRANCESCHI RT, RUTHERFORD RB: Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum. Gene Ther. (2000) 11:1201–1210.
   PubMed Web of Science ®Google Scholar
• RUTHERFORD RB, MOALLI M, FRANCESCHI RT, WANG D, GU K, KREBSBACH PH: Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone M vivo. Tissue Eng. (2002) 8:441–452.
   PubMedGoogle Scholar
• NUSSENBAUM B, RUTHERFORD RB, TEKNOS TN, DORNFELD KJ, KREBSBACH PH: Ex vivo gene therapy for skeletal regeneration in cranial defects compromised by postoperative radiotherapy. Hum. Gene Ther. (2003) 14:1107–1115.
   PubMed Web of Science ®Google Scholar
• JIN QM, ANUSAKSATHIEN O, WEBB SA, RUTHERFORD RB, GIANNOBILE WV: Gene therapy of bone morphogenetic protein for periodontal tissue engineering. Periodontol. (2003) 74:202–213.
   PubMed Web of Science ®Google Scholar
• DAYOUB H, DUMONT RJ, LI JZ et al: Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents. Tissue Eng. (2003) 9:347–356.
   PubMedGoogle Scholar
• DUMONT RJ, DAYOUB H, LI JZ et al: Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery (2002) 51:1239–1244.
   PubMed Web of Science ®Google Scholar
• BODEN SD, TITUS L, HAIR G et al: Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine (1998) 23:2486–1492.
   PubMed Web of Science ®Google Scholar
• VIGGESWARAPU M, BODEN SD, LIU Y et al.: Adenoviral delivery of LIM mineralization protein-1 induces new bone formation in vitro and in vivo. J. Bone Joint Surg. (2001) 83A:364–376.
   Google Scholar
• EINHORN T, MAJESKA RJ, MOHAIDEEN A et al.: A simple percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair. J. Bone Joint Surg. Am. Ed. (2003) 85A:1425–1435.
   Web of Science ®Google Scholar
• YAMAMOTO M, IKADA Y, TABATA Y: Controlled release of growth factors based on biodegradation of gelatin hydrogel. Biomat. Sci. Polym. Ed. (2001) 12:77–88.
   PubMed Web of Science ®Google Scholar
• SAITO N, OKADA T, HORIUCHI H et al.: A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat. Biotech. (2001) 19:332–335.
   PubMed Web of Science ®Google Scholar
• MAEDA H, SANO A, FUJIOKA K: Controlled release of rhBMP-2 from collagen minipellet and the relationship between the release profile and ectopic bone formation. Int. .1. Phann. (2004) 275:109–122.
   PubMed Web of Science ®Google Scholar
• LUTOLF MP, WEBER FE, SCHMOEKEL HG et al: Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat. Biotech. (2003) 21:513–519.
   PubMed Web of Science ®Google Scholar
• ULUDAG H, YANG J: Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotech. Frog. (2002) 18:604–611.
   Google Scholar
• GITTENS SA, MATYAS JR, ZERNICKE RE ULUDAG H: Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates. Phann. Res. (2003) 20:978–987.
   PubMed Web of Science ®Google Scholar
• GITTENS SA, KITOV PI, MATYAS JR, LOBENBERG R, ULUDAG H: Impact of tether length on the bone mineral affinity of protein-bisphosphonate conjugates. Phann. Res. (2004) 21:608–616.
   PubMed Web of Science ®Google Scholar
• BANSAL G, GITTENS SA, ULUDAG H: A di(bisphosphonic acid) for protein coupling and targeting to bone. Phann. Res. (2004) (In Press).
   PubMed Web of Science ®Google Scholar
• GAFNI Y, PELLED G, ZILBERMAN Y et al: Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol. The]: (2004) 9:587–595.
   PubMed Web of Science ®Google Scholar